Nevertheless, further studies were validated not only because there were indications that a subset of patients with moderately severe COPD might have benefitted by oxygen supplementation but also ...

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

Use of CT is proven to save lives in patients eligible for lung cancer screening, which includes most patients with COPD, said Barr, professor of medicine and epidemiology at Columbia University ...

Please provide your email address to receive an email when new articles are posted on . Patients with moderate or severe COPD experienced improvements with 3 mg of twice-daily ensifentrine. Study ...

March 27 (Reuters) - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful ...

Please provide your email address to receive an email when new articles are posted on . Across several subgroups, more patients receiving ensifentrine vs. placebo were classified as Transitional ...

The clinical and survival benefit of home oxygen therapy, both LTOT and nocturnal oxygen therapy, for patients with COPD and moderate hypoxemia was evaluated in this meta-analysis. Home oxygen therapy ...

WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive Phase III ETHOS trial showed AstraZeneca’s triple-combination therapy PT010 (budesonide ...

"The evidence we have in persons with mild-to-moderate COPD, or who are minimally symptomatic, on reducing exacerbations and improving quality of life is still very limited." — Jennifer S. Lin, MD, ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

On Friday, AstraZeneca Plc AZN released positive topline data from Phase 3 OBERON and TITANIA trials of tozorakimab in ...

GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.